after the limited but biologically fundamental clinical responses achieved by adoptive immunotherapy with interleukin-2 and lymphokine-activated killers , t cells appear to lend themselves as crucial new effectors in adoptive immunotherapy of human cancer and , in particular , of melanoma .
C0021756
interleukin-2
C0086418
human